CNS drugs approved by the centralised European procedure: true innovation or dangerous stagnation?

Author： Barbui Corrado Cipriani Andrea Lintas Camilla Bertelé Vittorio Garattini Silvio

ISSN： 0033-3158

Source： Psychopharmacology, Vol.190, Iss.2, 2007-02, pp. : 265-268

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Efficacy and safety of immunosuppressive drugs approved in EU through the centralised procedure

By Bertele’ Vittorio Buonocore Carmela Michelacci Francesca Vitocolonna Maria Garattini Silvio

European Journal of Clinical Pharmacology, Vol. 63, Iss. 7, 2007-07 ,pp. : 707-712

Springer Publishing Company

Access to resources Recommend Favorite

CNS Drugs III: Psychotherapeutics

By Marsden C.A. Stanford S.C.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 8, 2000-08 ,pp. : 1923-1929

Informa Healthcare

Access to resources Recommend Favorite

Improving the safety of newly approved drugs

Inpharma, Vol. 1, Iss. 1337, 2002-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Players in the European CNS Market

Pharmaceutical Innovation, Vol. 11, Iss. 6, 2002-10 ,pp. : 43-47

Adis International

Access to resources Recommend Favorite

Public misconceptions about FDA-approved drugs

Reactions Weekly, Vol. 1, Iss. 1372, 2011-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite